In both human and animal studies, they documented that COX-2 expression was associated with disease progression and poor clinical outcomes in various cancers, determining the role of COX-2 expression in prognostic values, such as disease-free interval and survival rate [24, 26, 56]. The gene discussed is PTGS2; the disease is cancer.